ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers
Patrick M. Hagan, Huiyu Ren, Sonja N. Brun…·Nicholas D. P. Cosford
The paper identifies SBP-1750, a ULK inhibitor that degrades ATG13 and kills KRAS-mutant cancer cells, showing efficacy in vivo and immune enhancement.